CD147 in Ovarian and Other Cancers
CD147 in Ovarian and Other Cancers
复制标题
DOI：
10.1097/igc.0b013e3182749139
复制
发表时间：
2013-01
期刊：
影响因子：
--
通讯作者：
Hong Yang;Biliang Chen
中科院分区：
文献类型：
--
作者：
Hong Yang;Biliang Chen
卵巢癌是一种妇科恶性肿瘤，是全世界老年妇女最常见的死亡原因。卵巢癌患者由于诊断较晚、远处转移及多药耐药等原因，5年总生存率仅为20%。因此，卵巢癌的早期诊断迫切需要预测和预后标志物。细胞外基质金属蛋白酶诱导剂CD147在卵巢癌中过度表达。目前的知识表明，CD147与卵巢癌的生存和进展有关，被认为是预后不良的生物标志物。在这里，我们特别回顾了CD147在卵巢癌进展中的作用，并讨论了CD147在卵巢癌患者中的诊断和预后价值。CD147通过参与恶性肿瘤的各个方面，包括侵袭、转移、存活、血管生成和耐药性，促进卵巢癌的进展。虽然尚未完全证实，但CD147与其他生物标志物的结合可能具有诊断价值。
Ovarian cancer, a gynecological malignancy, is the most common cause of death in older women worldwide. The overall 5-year survival of ovarian cancer patients is only 20% because of late diagnosis, as well as distant metastasis and multidrug resistance. Therefore, predictive and prognostic markers are urgently required for the early diagnosis of ovarian cancer. CD147, an extracellular matrix metalloproteinase inducer, is overexpressed in ovarian cancers. Current knowledge suggests that CD147 is associated with the survival and progression of ovarian cancer, and is considered as a biomarker of poor outcome. Here, we specifically review the roles of CD147 in ovarian cancer progression and discuss the diagnostic and prognostic value of CD147 in patients with ovarian cancer. CD147 promotes ovarian cancer progression by its involvement in every facet of malignancy, including invasion, metastasis, survival, angiogenesis, and drug resistance. Although it is not fully confirmed, the combination of CD147 with other biomarkers might be of diagnostic value.